Analytical Data
-
Gene name
CD69
- Application
-
Alternative Names
CD69; CLEC2-C; AIM; p60; EA1; MLR-3; Early T-Cell Activation Antigen p60; Early activation antigen CD69; Activation inducer molecule; Leukocyte surface antigen Leu-23
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q07108
-
Expression Region
Ser62~Lys199
-
Molecular Weight
20kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD69 is an early activation marker expressed on the surface of various immune cells, including T cells, B cells, and natural killer (NK) cells, following their activation. As an important molecule in the immune response, CD69 plays a critical role in regulating lymphocyte activation, migration, and the maintenance of immune homeostasis. The study of CD69 recombinant proteins has gained prominence due to their potential applications in understanding immune cell signaling pathways and developing immunotherapeutic strategies. Researchers have sought to produce CD69 in a recombinant form to facilitate detailed studies on its structure-function relationship, interactions with ligands, and the implications of its signaling in various diseases, including cancer and autoimmune disorders. The recombinant CD69 protein can be utilized in various experimental contexts, such as investigating the activation dynamics of immune cells in vitro, assessing the modulation of immune responses, and exploring the potential for CD69 as a therapeutic target. Overall, the exploration of CD69 recombinant proteins offers vital insights into immunological processes and opens avenues for novel therapeutic interventions based on immune modulation.
